The best mattress in a box is as high-quality as a bed you can find in a traditional brick-and-mortar store, but comes with the added bonus of delivering directly to your doorstep—no setup or ...

U.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, annual medical costs for obese patients increased by 46% to $18,507, with no ...

Semaglutide is better known as Ozempic, approved to treat type 2 diabetes, and Wegovy, for obesity; liraglutide is approved as Victoza for diabetes and Saxenda for obesity. And understanding the ...

Weight loss jabs could soon be given to tens of thousands of people in the UK. It is planned the new scheme would lower rates of obesity and ease the burden on the NHS - but people are being ...

The Government is considering using drugs to help get obese people back to work - but they can lead to serious health complications By Fiona Callingham, Health Reporter specialising in medical ...

The researchers analysed 4,000 obese participants aged 12 to 19 on semaglutide, the drug in Ozempic and Wegovy, or liraglutide, sold as Victoza and Saxenda. Their health data was them compared to ...

Copyright (C) 2022 by nekohasekai <[email protected]> This program is free software: you can redistribute it and/or modify it under the terms of the GNU ...

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

Novo Nordisk's Victoza (liraglutide) has become the only approved diabetes drug in the GLP-1 agonist class shown to demonstrate a cardiac safety benefit, although it faces competition from a ...